DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for hearing loss, X-linked 4 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHearing loss, X-linked 4 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hearing loss, x-linked 4 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Eya4-deficient mice all developed otitis media with effusion and had severe hearing deficits, with abnormal middle ear cavity and eustachian tube dysmorphology. In a large cohort of 539 patients with sporadic vestibular schwannoma followed for a mean of 7.7 years, more than 75% had nonserviceable hearing at last follow-up regardless of treatment strategy; active treatment with microsurgery or gamma knife surgery did not appear protective, and patients who were observed had the greatest probability of durable hearing. Among Swiss childhood cancer survivors diagnosed between 1976 and 2005, 10% reported hearing loss versus 3% of siblings, with the highest prevalence in central nervous system tumour survivors (25%); risk factors included platinum compounds (cisplatin odds ratio 9.4, carboplatin 2.4), cranial radiation above 29 Gy, and brain surgery, though the cumulative incidence of hearing loss decreased in the most recent treatment period (1996–2005).
For X-linked hearing loss specifically, four loci (DFN2, DFN3, DFN4, DFN6) had been implicated before a new classification (DFNX1-5) was proposed; POU3F4 was the first identified gene, and PRPS1 was later identified as the cause of DFNX1 (DFN2). In two Chinese families with DFNX4, point and frameshift mutations in SMPX caused gradual hearing loss with age. Smpx null mice showed progressive hearing loss starting at high frequency by the third month, with male mice affected earlier and more severely than females; hair cell bundles degenerated from the shortest row, with cellular edema and eventual cell death, and Smpx was expressed in stereocilia and appeared to participate in maintaining hair cell bundles after noise exposure.
The current standard of care for chronic sensorineural hearing loss remains hearing aids and cochlear implants; acute hearing loss is treated with systemic or intratympanic corticosteroids. Emerging therapies are being developed but face challenges in drug delivery to the inner ear, and the patient’s perspective on treatment burden is often overlooked. What is still missing are delivery methods that reliably reach the cochlea without additional harm, clinical trials that stratify patients by genetic subtype (such as DFNX4), and funding to move from mouse models to human studies for these rare X-linked forms.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Clinical Investigation · 2008 · 102 citations · open access
Eya4-deficient mice are a model for heritable otitis media
AbstractOtitis media is an extremely common pediatric inflammation of the middle ear that often causes pain and diminishes hearing. Vulnerability to otitis media is due to eustachian tube dysfunction as well as other poorly understood factors, including genetic susceptibility. As EYA4 mutations cause sensorineural hearing loss in humans, we produced and characterized Eya4-deficient (Eya4(-/-)) mice, which had severe hearing deficits. In addition, all Eya4(-/-) mice developed otitis media with effusion. Anatomic studies revealed abnormal middle ear cavity and eustachian tube dysmorphology; thus, Eya4 regulation is critical for the development and function of these structures. We suggest that some human otitis media susceptibility reflects underlying genetic predisposition in genes like EYA4 that regulate middle ear and eustachian tube anatomy.
Long-term Auditory Symptoms in Patients With Sporadic Vestibular Schwannoma
AbstractBACKGROUND: There are limited data on the long-term auditory symptoms in patients with sporadic small- and medium-sized vestibular schwannoma (VS). The initial treatment strategy for VS is controversial. OBJECTIVE: To characterize auditory symptoms in a large cohort of patients with VS. METHODS: Patients with ≤3 cm VS who underwent primary microsurgery, gamma knife surgery, or observation between 1998 and 2008 at 2 independent hospitals were identified. Clinical data were extracted from existing VS databases. At a mean time of 7.7 years after initial treatment, patients were surveyed via mail with the use of the Hearing Handicap Inventory for Adults (HHIA) and the Tinnitus Handicap Inventory. RESULTS: The response rate was 79%; a total of 539 respondents were analyzed. Overall, the hearing prognosis was poor, because more than 75% of all patients had nonserviceable hearing at the last clinical follow-up. Good baseline hearing proved to be a strong predictor for maintained serviceable hearing. Treatment modality was independently associated with both audiometric outcome and HHIA results. Active treatment with microsurgery or gamma knife surgery did not appear to be protective, because patients who were observed had the greatest probability of durable hearing. Patients in the surgical series had the greatest hearing loss. Tinnitus Handicap Inventory results were less predictable. The only predictors of tinnitus handicap were age and HHIA score. CONCLUSION: The overall prognosis for hearing in sporadic VS is poor regardless of treatment strategy. Treatment modality was an independent predictor of hearing status; observation was associated with the highest rate of hearing preservation. .
Long-term auditory complications after childhood cancer: A report from the Swiss Childhood Cancer Survivor Study
AbstractBACKGROUND: Auditory complications are an adverse event of childhood cancer treatment, especially common in children treated with platinum chemotherapy or cranial radiation. Variation between diagnostic childhood cancer groups has rarely been studied, and we do not know if the burden of auditory complications has changed over the last decades. PROCEDURE: Within the Swiss Childhood Cancer Survivor Study, we sent a questionnaire to all survivors who were diagnosed at age 16 years or less between 1976 and 2005. We compared prevalence of self-reported hearing loss and tinnitus between all diagnostic childhood cancer groups and siblings, used multivariable logistic regression to analyze the effect of treatment-related factors on hearing loss, and compared the cumulative incidence of hearing loss between different periods of cancer diagnosis. RESULTS: Prevalence of self-reported hearing loss was higher in survivors (10%) than in siblings (3%, P < 0.001), and highest in survivors of central nervous system tumors (25%). Significant risk factors were treatment with platinum compounds (carboplatin: odds ratio [OR] 2.4; cisplatin: OR 9.4), cranial radiation (>29 Gy: OR >1.7), or brain surgery (OR 2.2). Children diagnosed in 1986-1995, when platinum compounds came into widespread use, had a significantly higher cumulative incidence of hearing loss than those diagnosed in 1976-1985. In the most recent period, 1996-2005, the risk decreased again, both for patients treated with platinum compounds and with cranial radiation. CONCLUSIONS: Our data show that the burden of hearing loss has stabilized in recently treated survivors, suggesting that survivors have benefited from new treatment regimens that use less ototoxic radiation and more carefully dosed platinum compounds.
Frontiers in Bioscience-Elite · 2012 · 12 citations
Nonsyndromic X-linked hearing loss
AbstractTo date, 135 loci and 50 genes have been identified as causes of nonsyndromic hearing loss. Until recently, four loci (DFN2, DFN3, DFN4, and DFN6) had been implicated in nonsyndromic X-linked hearing loss; however, a new classification (DFNX1-5) has been proposed to reduce confusion in the terminology. The different types of nonsyndromic X-linked hearing loss demonstrate various clinical features in terms of the onset and progressiveness of hearing loss, pattern of audiogram, and the presence or absence of inner ear malformations. In addition to the POU3F4 gene, which was the first gene identified as causing nonsyndromic X-linked hearing loss, a second gene, PRPS1, has recently been identified to be the causative gene of DFNX1 (DFN2). This study reviews the new classification system, as well as the clinical features, molecular genetics, and developmental pathogenesis of different forms of nonsyndromic X-linked hearing loss.
Frontiers in Cellular Neuroscience · 2019 · 2 citations · open access
Delivering Therapeutics to the Cochlea: The Importance of the Patient’s Perspective
AbstractHearing loss represents a major sensory impairment in humans with a strong impact on quality of life. The current standard of care for chronic sensorineural hearing loss is limited to hearing aids and implantable devices like cochlear implants. Treatments for acute hearing loss consist of systemic or intratympanic corticosteroids. Emerging therapies are being developed to prevent hearing loss or to restore it at the cellular level. Many challenges and questions remain as to the delivery of these therapeutics into the inner ear. Scientists, clinicians, and industry stakeholders should always consider the treatment burden from the patient's perspective when designing new drug delivery approaches. This article highlights key issues to consider.
Image_1_SMPX Deficiency Causes Stereocilia Degeneration and Progressive Hearing Loss in CBA/CaJ Mice.JPEG
Abstract<p>The small muscle protein, x-linked (SMPX) encodes a small protein containing 88 amino acids. Malfunction of this protein can cause a sex-linked non-syndromic hearing loss, named X-linked deafness 4 (DFNX4). Herein, we reported a point mutation and a frameshift mutation in two Chinese families who developed gradual hearing loss with age. To explore the impaired sites in the hearing system and the mechanism of DFNX4, we established and validated an Smpx null mouse model using CRISPR-Cas9. By analyzing auditory brainstem response (ABR), male Smpx null mice showed a progressive hearing loss starting from high frequency at the 3rd month. Hearing loss in female mice was milder and occurred later compared to male mice, which was very similar to human beings. Through morphological analyses of mice cochleas, we found the hair cell bundles progressively degenerated from the shortest row. Cellular edema occurred at the end phase of stereocilia degeneration, followed by cell death. By transfecting exogenous fluorescent Smpx into living hair cells, Smpx was observed to be expressed in stereocilia. Through noise exposure, it was shown that Smpx might participate in maintaining hair cell bundles. This Smpx knock-out mouse might be used as a suitable model to explore the pathology of DFNX4.</p>
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
